A new needle-free option for severe allergy treatment starts to break the long-standing grip of the familiar injector, and the market treats it like a losing fight between two newcomers. The more interesting angle is that both newcomers could grow the whole category by winning over people who avoid needles—if they can navigate insurance gatekeepers and a fast-approaching head‑to‑head launch.Read more
Needle-free emergency allergy treatment is gaining traction with parents, schools, and insurers, and ARS Pharmaceuticals aims to turn that shift into a much bigger business as neffy rolls out to more countries and potential new uses. But with so much riding on one product and heavy spending to drive awareness, stronger competition or tougher pricing could quickly change the story.Read more
ARS Pharmaceuticals is riding early demand for a needle-free allergy rescue treatment, but its future hinges on whether insurers and regulators keep access easy and pricing stable. The bigger question is whether a one-product company can keep growth going as competition heats up and marketing and rebate costs rise.Read more
Key Takeaways Neffy's needle-free delivery is expanding the allergy treatment market, attracting previously untreated patients and driving greater-than-expected revenue and prescription growth. Enhanced insurance coverage, multi-pack purchasing, and strategic positioning are accelerating recurring sales, expanding margins, and making ARS attractive for global partnerships or acquisition.Read more
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
